Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

AZ: We have to be able to show mHealth can work

Still room for improvement in mobile health, Andy Jones tells ThinkDigital

AstraZeneca Me&MyCOPD Android mobile appMore work is necessary for pharma to prove its mHealth initiatives can lift patient outcomes, according to AstraZeneca.

The company's Andy Jones told DigitasHealth Lifebrands' ThinkDigital event in London earlier this week that current uses of mobile health technology can be improved.

Jones, who heads up AstraZeneca's Intelligence Pharmaceuticals Group, said: “We think we can do better than the current level of mobile health. We think we can do better by putting the patient at the heart of an integrated system.

“But it is vitally important in the mHealth system that we demonstrate these things work - our goal is to run clinical evaluations to demonstrate improved outcomes.”

As part of this mission AZ is currently putting its Me&MyCOPD service, which the company is developing with Exco Intouch, though a clinical trial in the north-west of England. See a picture of the Android app above.

The digital health support service aims to enhance patient management of their condition by combining mobile devices with medication and symptom monitoring.

Me&MyCOPD uses Bluetooth monitoring of the inhaled medication and patients enrolled on the UK programme will be offered personalised coaching and real-time information about their disease and treatment, enabling them to collect, transmit and review their own clinical data.

AstraZeneca is also poised to begin US tests of a web and smartphone-based self-management tool for patients with diabetes. Patient pilots of the service, which aims to help patients manage their disease, make lifestyle changes and delay the need for insulin, are set to begin in December.

Earlier this year the company signed a further mHealth partnership, this time with Vodafone and will work with the telecoms giant to develop a range of mHealth services for patients with cardiovascular conditions.

“[If] you have a drug that works you have to make sure patients get all the support they can to make sure they use it well, because then you will get a better outcome - that's what we believe,” Jones said.

26th September 2014

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics